TransMedics Group, Inc. stock discussion
TMDX by GPT4, PPt earning call# TransMedics OCS™ Clinical Outcomes:
- **OCS™ Lung**:
- 87% utilization of DBD & DCD lungs
- 50% reduction in severe complications
- **OCS™ Heart**:
- 81% utilization of DBD hearts
- 65% lower severe complications
- 95% patient survival after DCD transplants
- **OCS™ Liver**:
- Doubled DCD liver utilization
- 43% less severe complications
- 84% fewer long-term biliary complications
Growth Strategy:
- Expand logistics and support for the National OCS Program
- Focus on OCS™ Lung adoption
- Long-term goals include next-gen OCS™, increased transplant volume, and OUS reimbursement.
For detailed information, refer to TransMedics' official publications and data.